Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 9:40 a.m. ET. The event will include a fireside chat accessible via the company’s Events page, with the webcast archived for at least thirty days. Founded in 1996, Royalty Pharma is a leader in funding biopharmaceutical innovation, holding royalties on approximately 40 commercial products from major pharmaceutical companies, facilitating advancements in healthcare.

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4^th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When is Royalty Pharma's participation in the Evercore ISI HealthCONx Conference?

Royalty Pharma will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 9:40 a.m. ET.

How can I access the Royalty Pharma webcast for the HealthCONx Conference?

The webcast for the Royalty Pharma HealthCONx Conference will be accessible on their Events page at https://www.royaltypharma.com/investors/news-and-events/events.

Will the Royalty Pharma webcast be available after the event?

Yes, the Royalty Pharma webcast will be archived for a minimum of thirty days after the event.

What is the stock symbol for Royalty Pharma?

The stock symbol for Royalty Pharma is RPRX.

What type of products does Royalty Pharma hold royalties on?

Royalty Pharma holds royalties on around 40 commercial products, including therapies from AbbVie, Johnson & Johnson, and Biogen.